R

Reapplix

31 employees

Reapplix identifies blood-derived proteins that improve wound healing, isolates them, and reapplies them to patients with chronic wounds.

Basic info

Industry

medical equipment manufacturing

Sectors

Medical Device
Biotechnology
Therapeutics
Advanced wound care
medical device
PRP
wound therapy

Date founded

2008

Funding rounds raised

Total raised

$23M

from 7 investors over 7 rounds

R

Reapplix raised $23M on July 13, 2020

Investors: Lauxera Capital Partners

R

Reapplix raised $3.7M on October 10, 2019

Investors: SEED Capital Denmark, Vækstfonden and Novo Holdings

R

Reapplix raised $3M on September 27, 2016

Investors: Vækstfonden, SEED Capital Denmark and Novo Holdings

FAQ